White House advisory group calls systems engineering key to healthcare transformation

A presidential advisory group of scientists asserts that systems engineering holds the key to better healthcare and lower costs.

The 66-page report by the President’s Council of Advisors on Science and Technology identifies a comprehensive set of actions for enhancing U.S. healthcare through greater use of systems-engineering principles.

“Systems engineering, widely used in manufacturing and aviation, is an interdisciplinary approach to analyze, design, manage and measure a complex system in order to improve its efficiency, reliability, productivity, quality and safety,” wrote the advisory board. “It has often produced dramatically positive results in the small number of healthcare organizations that have incorporated it into their processes. But in spite of excellent examples, systems methods and tools are not yet used on a widespread basis in U.S. healthcare.”

As such, in addition to accelerating movement to a payment system that pays for value rather than volume, the advisory board recommends providing technical assistance to healthcare providers in applying systems methods, particularly those with limited resources. Also, it recommends bolstering engagement with communities to help improve healthcare delivery.

“Systems engineering know-how must be propagated at all levels” so the U.S. can “build a healthcare workforce that is equipped with essential systems engineering competencies that will enable system redesign.”

Read the full report here.

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.